Rare Commons: an innovative social media platform 2.0 for collaborative clinical research on pediatric rare diseases



Main Author – Begonya Nafria

Ms. Begonya Nafría (F), MsC, Patient Advocacy Manager at Institut de Recerca Sant Joan de Déu and Fundació Sant Joan de Déu. Experience in coordinating and managing projects in clinical research on rare diseases. Coordinator of YPAG (Young Persons’ Advisory Group)-KIDS Barcelona and RareCommons platform. Ms. Nafría is the Coordinator of eYPAGnet (European YPAG network – accredited by EnprEMA), Member of the Course Committee of Eupati (European Patients’ Academy on Therapeutic Innovation) and Chair of the Educational Committee of ICAN (International Children Advisory Network).

This poster was presented as part of the EURO-NMD 1st Annual Meeting - Freiburg, Germany in November, 2017.

Contact Begonya Nafria about this poster at bnafria@sjdhospitalbarcelona.org.

Additional authors

Nafría B (1), Vroom E (2), Athanasiou D (2)

(1) Institut de Recerca Sant Joan de Déu and Fundació Sant Joan de Déu,
(2) United Parent Projects Muscular Dystrophy

Email for correspondence: rarecommons@sjdhospitalbarcelona.org

The use of social media for patients education is already a common use in the medical field, although not so frequent in pediatric rare diseases. Rare Commons (RC) is a research project focused on the biomedical study of rare diseases affecting children, that uses a social media platform where patients and families collaborate together to generate scientific knowledge.
The methodology of collaboration is based on the Collective Intelligence Theory (Malone, 2014), on the Crowdsourced Health Research Studies (Swan, 2012) and on the expertise accumulated with 9 projects that are ongoing in RC. It is based in an easy cycle that is repeated for everybody system that is affected by a disease (genetics, neurology …). One cycle is: easy reading chapter about one system, exhaustive survey to collect clinical data and a summary of the statistical data collected.
The method and every project has the approval of the Ethics Committee and therefore all the families complete and sign the informed consent to participate in the project.
We are going to design a specific community to study the different neuromuscular disorders that form part of this category and at the same time included in the group of rare diseases. The goals of the project will be:
1. To increase the knowledge about the natural history, its clinical and biochemical characteristics, and genotype and phenotype correlations.
2. To develop algorithms of clinical suspicions and diagnosis that will facilitate early diagnosis.
3. To generate relevant information for participating families focused on the disease self-management, with professional support to complement, but not replace, medical advice.
4. To create exhaustive clinical patients’ registers with the aim to have epidemiological valid data.
CONCLUSION:
The best tool and methodology to develop international research projects on rare diseases are social media and the collaboration between different agents (patients, families and clinicians), it facilitates the collection of clinical smart data through large and international samples of patients.

The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission


“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit ec.europa.eu/health/ern